18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
Ziren Kong(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenbin Ma(Hangzhou Dianzi University), Chendan Jiang(Capital Medical University), Yusong Lin, Xin Cheng(Chengdu University of Technology), Jie Tian(Shanghai Jiao Tong University), Longfei Li(Huazhong Agricultural University), Zehua Liu(Zhengzhou University), Xuying Qin(Tianjin University of Science and Technology), Yuekun Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhenyu Liu(Shanxi Agricultural University), Congxin Dai(The University of Texas MD Anderson Cancer Center), Yu Wang(Sichuan University), Delin Liu(Second Military Medical University)
Cited by 47
Related Papers
The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges
|Theranostics|2019|1k
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
|Clinical Cancer Research|2017|562
Central focused convolutional neural networks: Developing a data-driven model for lung nodule segmentation
|Medical Image Analysis|2017|489
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482